Arrowstreet Capital’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

Arrowstreet Capital’s Portfolio CBPO Stock Details CBPO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-60,607	Closed	-$7.16M	–	2696
2020 Q4	$7.16M	Sell	60,607 -47,394	-44%	-$5.5M	0.01%	1034
2020 Q3	$12M	Sell	108,001 -67,237	-38%	-$7.22M	0.02%	761
2020 Q2	$17.9M	Buy	175,238 +90,746	+107%	+$9.71M	0.03%	545
2020 Q1	$9.12M	Buy	+84,492	New	+$9.71M	0.03%	514
2016 Q1	–	Sell	-124,639	Closed	-$17.7M	–	1698
2015 Q4	$17.7M	Buy	124,639 +36,055	+41%	+$4.16M	0.08%	244
2015 Q3	$7.97M	Buy	88,584 +68,693	+345%	+$7.25M	0.04%	410
2015 Q2	$2.29M	Buy	+19,891	New	+$2.09M	0.01%	604

Other funds holding CBPO

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Athos Capital Hong Kong $324M AUM 16.62% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MCP

Maso Capital Partners Hong Kong $60.9M AUM 0.32% 1-Year Est. Return

OMC

Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Arrowstreet Capital's CBPO Position: Q1 2021 in Review

Arrowstreet Capital sold out of China Biologic Products Holdings, Inc. (CBPO) in Q1 2021, closing a stake of 60,607 shares — an estimated $7.16M sold.

Arrowstreet Capital first reported a position in CBPO in Q2 2015 and held it in 7 quarters. The position peaked at $17.9M in Q2 2020. 86 funds tracked by Wall St. Rank hold CBPO as of Q1 2021.

Arrowstreet Capital reported no remaining China Biologic Products Holdings, Inc. position as of Q1 2021 after selling out during the quarter.
Arrowstreet Capital sold 60,607 China Biologic Products Holdings, Inc. shares in Q1 2021, an estimated $7.16M.
Arrowstreet Capital first reported a position in China Biologic Products Holdings, Inc. in Q2 2015 and held it in 7 quarters.
Arrowstreet Capital's China Biologic Products Holdings, Inc. position peaked at $17.9M in Q2 2020.
86 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q1 2021.

Based on Arrowstreet Capital's 13F filing for Q1 2021, filed 14 May 2021.